Form D · Investing
NEOPHARM PHARMACANN INVESTORS II, LLC
Chicago, IL · CIK 0001698261
Offering snapshot reported Mar 9, 2017 · SEC filing
- Reported sold
- $3.55M Offering amount: $20M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $150K Reported outside-investor minimum
- First sale
- Feb 28, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 9, 2017 | Initial | $3,550,000 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-282173
Source: Form D, filed Mar 9, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Patrick Barry | Executive |
| Joseph Flanagan | Executive |
| James Flanigan, Jr. | Executive |
| Brad Leshnock | Executive |
| John Wagner | Executive |
Issuer details
Industry: Investing (See others in industry)
Address:
300 South Wacker Drive Ste 2750
Chicago, IL, 60606
Chicago, IL, 60606